Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to evaluate the safety of switching from a toxicity-causing antiretroviral (ARV) therapy to Fuzeon [enfuvirtide] in patients with ARV treatment-limiting toxicities

Next Previous
X
Search
Trial Profile

An open-label study to evaluate the safety of switching from a toxicity-causing antiretroviral (ARV) therapy to Fuzeon [enfuvirtide] in patients with ARV treatment-limiting toxicities

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfuvirtide (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms SWITCH TOX
  • Sponsors Roche

    • Most Recent Events

    • 19 Jul 2012 Planned number of patients changed from 100 to 300 as reported by European Clinical Trials Database.
    • 24 May 2007 Status change from in progress to completed.
    • 22 Nov 2006 Interim results reported from the 8th International Congress on Drug Therapy in HIV Infection.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top